Search : Conferences and Meetings

2026 Highlights of ASH in Latin America, 2026 Highlights of ASH in Latin America (ES), Highlights of ASH in Latin America (PT)

Oral and Poster Abstracts, Marquee Sessions, Education Program, Scientific Symposia, Special-Interest Sessions, Spotlight Sessions, Trainee Activities and Services, Scientific Program

Marquee Sessions, Education Program, Scientific Symposia, Special-Interest Sessions, Spotlight Sessions, Trainee Activities and Services, Scientific Program

Marquee Sessions, Education Program, Scientific Symposia, Special-Interest Sessions, Spotlight Sessions, Trainee Activities and Services

Trainee Activities and Services, Spotlight Sessions, Special-Interest Sessions, Scientific Symposia, Scientific Program, Marquee Sessions

401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I, 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II, 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III, 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I, 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II, 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III, 506. Bone Marrow Microenvironment: Poster I, 506. Bone Marrow Microenvironment: Poster II, 506. Bone Marrow Microenvironment: Poster III, 508. Bone Marrow Failure: Acquired: Poster I, 508. Bone Marrow Failure: Acquired: Poster II, 508. Bone Marrow Failure: Acquired: Poster III, 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I, 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II, 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III

401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I, 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II, 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III, 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I, 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II, 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III, 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster I, 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster II, 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III, 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I, 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II, 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III, 621. Lymphomas: Translational Molecular and Genetic: Poster I, 621. Lymphomas: Translational Molecular and Genetic: Poster II, 621. Lymphomas: Translational Molecular and Genetic: Poster III, 622. Lymphomas: Translational Non-Genetic: Poster I, 622. Lymphomas: Translational Non-Genetic: Poster II, 622. Lymphomas: Translational Non-Genetic: Poster III, 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I, 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II, 623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III, 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I, 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II, 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III, 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I, 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II, 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III, 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster I, 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster II, 626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster III, 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster I, 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II, 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster III, 628. Aggressive Lymphomas: Cellular Therapies: Poster I, 628. Aggressive Lymphomas: Cellular Therapies: Poster II, 628. Aggressive Lymphomas: Cellular Therapies: Poster III, 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster I, 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster II, 629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Poster III, 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I, 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II, 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III, 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I, 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II, 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III

401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I, 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II, 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III, 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I, 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II, 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III, 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I, 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II, 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III, 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I, 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II, 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III, 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I, 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II, 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III, 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster I, 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster II, 619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster III, 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I, 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II, 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III, 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I, 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II, 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III, 636. Myelodysplastic Syndromes: Basic and Translational: Poster I, 636. Myelodysplastic Syndromes: Basic and Translational: Poster II, 636. Myelodysplastic Syndromes: Basic and Translational: Poster III, 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I, 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II, 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III, 908. Outcomes Research: Myeloid Malignancies: Poster I, 908. Outcomes Research: Myeloid Malignancies: Poster II, 908. Outcomes Research: Myeloid Malignancies: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III

401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 602. Myeloid Oncogenesis: Basic: Poster I, 602. Myeloid Oncogenesis: Basic: Poster II, 602. Myeloid Oncogenesis: Basic: Poster III, 603. Lymphoid Oncogenesis: Basic: Poster I, 603. Lymphoid Oncogenesis: Basic: Poster II, 603. Lymphoid Oncogenesis: Basic: Poster III, 621. Lymphomas: Translational Molecular and Genetic: Poster I, 621. Lymphomas: Translational Molecular and Genetic: Poster II, 621. Lymphomas: Translational Molecular and Genetic: Poster III, 702. CAR-T Cell Therapies: Basic and Translational: Poster I, 702. CAR-T Cell Therapies: Basic and Translational: Poster II, 702. CAR-T Cell Therapies: Basic and Translational: Poster III, 801. Gene Therapies: Poster I, 801. Gene Therapies: Poster II, 801. Gene Therapies: Poster III, 802. Chemical Biology and Experimental Therapeutics: Poster I, 802. Chemical Biology and Experimental Therapeutics: Poster II, 802. Chemical Biology and Experimental Therapeutics: Poster III, 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I, 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II, 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III

301. Platelets and Megakaryocytes: Basic and Translational: Poster I, 301. Platelets and Megakaryocytes: Basic and Translational: Poster II, 301. Platelets and Megakaryocytes: Basic and Translational: Poster III, 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I, 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II, 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III, 321. Coagulation and Fibrinolysis: Basic and Translational: Poster I, 321. Coagulation and Fibrinolysis: Basic and Translational: Poster II, 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III, 322. Hemophilia A and B: Clinical and Epidemiological: Poster I, 322. Hemophilia A and B: Clinical and Epidemiological: Poster II, 322. Hemophilia A and B: Clinical and Epidemiological: Poster III, 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I, 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II, 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III, 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I, 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II, 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III, 401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I, 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II, 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III, 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I, 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II, 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I, 101. Red Cells and Erythropoiesis, Excluding Iron: Poster II, 101. Red Cells and Erythropoiesis, Excluding Iron: Poster III, 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster I, 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster II, 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster III, 112. Thalassemia and Globin Gene Regulation: Poster I, 112. Thalassemia and Globin Gene Regulation: Poster II, 112. Thalassemia and Globin Gene Regulation: Poster III, 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I, 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II, 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III, 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I, 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II, 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III, 401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I, 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II, 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III

401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II, 900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III, 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I, 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II, 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III, 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I, 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II, 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III, 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I, 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II, 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III, 904. Outcomes Research: Hemoglobinopathies: Poster I, 904. Outcomes Research: Hemoglobinopathies: Poster II, 904. Outcomes Research: Hemoglobinopathies: Poster III, 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I, 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II, 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III, 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I, 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II, 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III, 907. Outcomes Research: Plasma Cell Disorders: Poster I, 907. Outcomes Research: Plasma Cell Disorders: Poster II, 907. Outcomes Research: Plasma Cell Disorders: Poster III, 908. Outcomes Research: Myeloid Malignancies: Poster I, 908. Outcomes Research: Myeloid Malignancies: Poster II, 908. Outcomes Research: Myeloid Malignancies: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III

201. Granulocytes, Monocytes, and Macrophages: Poster I, 201. Granulocytes, Monocytes, and Macrophages: Poster II, 201. Granulocytes, Monocytes, and Macrophages: Poster III, 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I, 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II, 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III, 401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 701. Experimental Transplantation: Basic and Translational: Poster I, 701. Experimental Transplantation: Basic and Translational: Poster II, 701. Experimental Transplantation: Basic and Translational: Poster III, 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I, 703. Cellular Immunotherapies other than CAR-T Cells: Poster II, 703. Cellular Immunotherapies other than CAR-T Cells: Poster III, 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I, 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II, 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III, 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I, 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II, 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III, 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I, 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II, 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III, 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I, 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II, 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III, 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I, 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II, 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III, 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I, 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II, 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III

401. Blood Transfusion: Poster I, 401. Blood Transfusion: Poster II, 401. Blood Transfusion: Poster III, 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I, 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II, 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III, 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I, 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II, 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III, 653. Multiple Myeloma: Clinical and Epidemiological: Poster I, 653. Multiple Myeloma: Clinical and Epidemiological: Poster II, 653. Multiple Myeloma: Clinical and Epidemiological: Poster III, 654. Multiple Myeloma: Pharmacologic Therapies: Poster I, 654. Multiple Myeloma: Pharmacologic Therapies: Poster II, 654. Multiple Myeloma: Pharmacologic Therapies: Poster III, 655. Multiple Myeloma: Cellular Therapies: Poster I, 655. Multiple Myeloma: Cellular Therapies: Poster II, 655. Multiple Myeloma: Cellular Therapies: Poster III, 907. Outcomes Research: Plasma Cell Disorders: Poster I, 907. Outcomes Research: Plasma Cell Disorders: Poster II, 907. Outcomes Research: Plasma Cell Disorders: Poster III, 909. Education, Communication, and Workforce: Poster I, 909. Education, Communication, and Workforce: Poster II, 909. Education, Communication, and Workforce: Poster III

Education Program, General Sessions, Oral Abstracts, Scientific Program, Scientific Symposia, Special-Interest Sessions, Spotlight Sessions, Trainee Activities and Services

Education Program, General Sessions, Scientific Program, Scientific Symposia, Special-Interest Sessions, Spotlight Sessions, Trainee Activities and Services

Education Program, General Sessions, Special-Interest Sessions, Spotlight Sessions, Trainee Activities and Services

General Sessions, Scientific Program, Scientific Symposia, Special-Interest Sessions, Spotlight Sessions, Trainee Activities and Services